Related references
Note: Only part of the references are listed.Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey et al.
CLINICAL CANCER RESEARCH (2022)
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Hedy L Kindler et al.
LANCET ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors
Bernadette Xin Jie Tune et al.
JOURNAL OF ONCOLOGY (2022)
A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
Stephanie Lheureux et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.
Pavlina Spiliopoulou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Identification of Potential Prognostic Biomarkers Associated with Monocyte Infiltration in Lung Squamous Cell Carcinoma
Hailin Liu et al.
BIOMED RESEARCH INTERNATIONAL (2022)
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
Renee Bouwstra et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
Tyvette S. Hilliard et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J. Luke et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
Federica Grosso et al.
DIAGNOSTICS (2021)
Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
Takahiro Einama et al.
BIOMARKER RESEARCH (2021)
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Soren Weidemann et al.
BIOMEDICINES (2021)
Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer
Ken Nagata et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness
Soren Weidemann et al.
CANCER INVESTIGATION (2021)
Prevalence of mesothelin expression in peritoneal disease from colorectal and appendiceal cancers
Dong H. Yoon et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway
Qianyu Huo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Christine Alewine et al.
CLINICAL CANCER RESEARCH (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation
Ricardo Coelho et al.
ONCOGENESIS (2020)
Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells
Lea Lazzerini et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Raffit Hassan et al.
CANCER (2020)
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models
Qun Jiang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Multiple proteases are involved in mesothelin shedding by cancer cells
Xiufen Liu et al.
COMMUNICATIONS BIOLOGY (2020)
Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
Kai Le et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
The basics of epithelial-mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective
Vishal Das et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression
Vincenzo Fontana et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer
Su-Jin Shin et al.
ONCOLOGIST (2019)
Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer
Takuya Shiraishi et al.
BMC CANCER (2019)
Mesothelin expression has prognostic value in stage / colorectal cancer
Takehiro Shiraishi et al.
VIRCHOWS ARCHIV (2019)
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
Yasmin Leshem et al.
TOXINS (2018)
Phase lb study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer
Raffit Hassan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Jingli Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Mesothelin-targeted immunotoxin RG7787 has synergistic antitumor activity when combined with taxanes
Emily Kolyvas et al.
ONCOTARGET (2017)
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
Shingo Inaguma et al.
ONCOTARGET (2017)
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
Takashi Eguchi et al.
ONCOTARGET (2017)
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity
Yasmin Leshem et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
Song-Hee Han et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2017)
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D. Weekes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers
Ibrahim Vedat Bayoglu et al.
BIOMEDICINE & PHARMACOTHERAPY (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
Yi-Fan Zhang et al.
SCIENTIFIC REPORTS (2015)
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Yasuhito Fujisaka et al.
INVESTIGATIONAL NEW DRUGS (2015)
Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer
Xiaohua Wu et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2014)
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
Mark Linch et al.
BMC CANCER (2014)
Mesothelin expression is associated with poor outcomes in breast cancer
Yun R. Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Phase 1 Study of the Antimesothelin Immunotoxin SS1P in Combination With Pemetrexed and Cisplatin for Front-Line Therapy of Pleural Mesothelioma and Correlation of Tumor Response With Serum Mesothelin, Megakaryocyte Potentiating Factor, and Cancer Antigen 125
Raffit Hassan et al.
CANCER (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
Jingli Zhang et al.
PLOS ONE (2014)
Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer
Napa Parinyanitikul et al.
CLINICAL BREAST CANCER (2013)
Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Fiona Collinson et al.
CLINICAL CANCER RESEARCH (2013)
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
Douglas W. Henderson et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA
Douglas W. Henderson et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin
Sharmila Shankar et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
Shih-Hsun Chen et al.
SCIENTIFIC REPORTS (2013)
Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
Ming-Cheng Chang et al.
BIOCHEMICAL JOURNAL (2012)
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Futoshi Kawamata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis
Kevin Hollevoet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mesothelin expression correlates with prolonged patient survival in gastric cancer
Kenji Baba et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
Yujian Zhang et al.
CANCER RESEARCH (2011)
Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation
Uddalak Bharadwaj et al.
CARCINOGENESIS (2011)
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
Uddalak Bharadwaj et al.
MOLECULAR CANCER (2011)
Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma
Takahiro Einama et al.
PANCREAS (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2010)
Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Raffit Hassan et al.
LUNG CANCER (2010)
Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway
Ming-Cheng Chang et al.
BIOCHEMICAL JOURNAL (2009)
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
W-F Cheng et al.
BRITISH JOURNAL OF CANCER (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
A Binding Domain on Mesothelin for CA125/MUC16
Osamu Kaneko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
Yujian Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
Alfonso Cristaudo et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice
YuJian Zhang et al.
CLINICAL CANCER RESEARCH (2006)
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
R Hassan et al.
CLINICAL CANCER RESEARCH (2006)
Mesothelin-family proteins and diagnosis of mesothelioma
BWS Robinson et al.
LANCET (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Application of mesothelin immunostaining in tumor diagnosis
NG Ordonez
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
The significance of serum CA 125 elevation in malignant and nonmalignant diseases
K Sjövall et al.
GYNECOLOGIC ONCOLOGY (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
Mesothelin is not required for normal mouse development or reproduction
TK Bera et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
